Upexi (UPXI) Competitors $4.60 -0.04 (-0.86%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.58 -0.01 (-0.33%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock UPXI vs. ARWR, TWST, HRMY, IDYA, IRON, MESO, CNTA, VCEL, CGON, and DNLIShould you be buying Upexi stock or one of its competitors? The main competitors of Upexi include Arrowhead Pharmaceuticals (ARWR), Twist Bioscience (TWST), Harmony Biosciences (HRMY), IDEAYA Biosciences (IDYA), Disc Medicine (IRON), Mesoblast (MESO), Centessa Pharmaceuticals (CNTA), Vericel (VCEL), CG Oncology (CGON), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry. Upexi vs. Its Competitors Arrowhead Pharmaceuticals Twist Bioscience Harmony Biosciences IDEAYA Biosciences Disc Medicine Mesoblast Centessa Pharmaceuticals Vericel CG Oncology Denali Therapeutics Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Upexi (NASDAQ:UPXI) are both pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment. Is ARWR or UPXI more profitable? Arrowhead Pharmaceuticals has a net margin of 0.00% compared to Upexi's net margin of -135.86%. Arrowhead Pharmaceuticals' return on equity of -45.33% beat Upexi's return on equity.Company Net Margins Return on Equity Return on Assets Arrowhead PharmaceuticalsN/A -45.33% -12.49% Upexi -135.86%-535.19%-122.94% Which has more volatility and risk, ARWR or UPXI? Arrowhead Pharmaceuticals has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Upexi has a beta of -0.52, indicating that its stock price is 152% less volatile than the S&P 500. Do institutionals and insiders have more ownership in ARWR or UPXI? 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 5.7% of Upexi shares are held by institutional investors. 4.3% of Arrowhead Pharmaceuticals shares are held by company insiders. Comparatively, 31.6% of Upexi shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media prefer ARWR or UPXI? In the previous week, Arrowhead Pharmaceuticals had 1 more articles in the media than Upexi. MarketBeat recorded 11 mentions for Arrowhead Pharmaceuticals and 10 mentions for Upexi. Upexi's average media sentiment score of 0.98 beat Arrowhead Pharmaceuticals' score of 0.84 indicating that Upexi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Upexi 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend ARWR or UPXI? Arrowhead Pharmaceuticals currently has a consensus target price of $43.71, indicating a potential upside of 174.41%. Upexi has a consensus target price of $16.00, indicating a potential upside of 247.83%. Given Upexi's stronger consensus rating and higher possible upside, analysts plainly believe Upexi is more favorable than Arrowhead Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arrowhead Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.89Upexi 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable valuation and earnings, ARWR or UPXI? Upexi has higher revenue and earnings than Arrowhead Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArrowhead Pharmaceuticals$3.55M619.70-$599.49M-$1.40-11.38Upexi$26M15.81-$23.66MN/AN/A SummaryArrowhead Pharmaceuticals beats Upexi on 9 of the 15 factors compared between the two stocks. Get Upexi News Delivered to You Automatically Sign up to receive the latest news and ratings for UPXI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UPXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UPXI vs. The Competition Export to ExcelMetricUpexiTechnology Services IndustryBusiness SectorNASDAQ ExchangeMarket Cap$411.07M$2.45B$14.73B$9.37BDividend YieldN/A1.62%2.86%4.12%P/E RatioN/A19.1424.2823.79Price / Sales15.8135.5040.7596.30Price / CashN/A43.3826.1157.18Price / Book0.745.085.085.54Net Income-$23.66M$33.55M$196.77M$259.88M7 Day Performance-24.71%-4.62%-4.30%-4.67%1 Month Performance59.17%0.59%-1.16%4.40%1 Year Performance-16.97%48.85%28.86%17.91% Upexi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UPXIUpexi3.7367 of 5 stars$4.60-0.9%$16.00+247.8%-32.3%$411.07M$26M0.00130Insider TradeGap DownARWRArrowhead Pharmaceuticals3.825 of 5 stars$16.20+2.9%$43.71+169.8%-42.0%$2.17B$3.55M-11.57400News CoveragePositive NewsUpcoming EarningsGap UpTWSTTwist Bioscience3.551 of 5 stars$36.53+1.5%$50.40+38.0%-36.5%$2.16B$312.97M-11.24990News CoverageUpcoming EarningsShort Interest ↑Gap DownHRMYHarmony Biosciences4.7766 of 5 stars$35.76-4.7%$51.00+42.6%+5.1%$2.15B$744.85M13.65200Positive NewsUpcoming EarningsIDYAIDEAYA Biosciences4.1756 of 5 stars$25.02+2.1%$48.09+92.2%-42.8%$2.15B$7M-6.9780Upcoming EarningsGap UpHigh Trading VolumeIRONDisc Medicine3.5378 of 5 stars$59.48-1.9%$95.73+60.9%+36.3%$2.10BN/A-15.1730Positive NewsUpcoming EarningsInsider TradeMESOMesoblast0.7705 of 5 stars$15.93-2.6%$18.00+13.0%+141.2%$2.09B$5.90M0.0080CNTACentessa Pharmaceuticals3.1977 of 5 stars$15.20-1.4%$28.10+84.9%+63.4%$2.06B$6.85M-8.40200News CoverageAnalyst ForecastInsider TradeVCELVericel2.2469 of 5 stars$41.45+3.3%$61.14+47.5%-25.0%$2.02B$237.22M1,382.13300Trending NewsEarnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionCGONCG Oncology1.9068 of 5 stars$25.86-0.9%$55.30+113.8%-22.3%$1.99B$662K-17.1361News CoverageGap DownDNLIDenali Therapeutics4.5764 of 5 stars$13.63-0.3%$33.71+147.4%-42.4%$1.99B$330.53M-5.10430News CoverageUpcoming Earnings Related Companies and Tools Related Companies ARWR Alternatives TWST Alternatives HRMY Alternatives IDYA Alternatives IRON Alternatives MESO Alternatives CNTA Alternatives VCEL Alternatives CGON Alternatives DNLI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UPXI) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Upexi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Upexi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free UPXI Stock Alerts